Arkolith/Insider Trading/XERS/Form 4

Bormann-Kennedy Barbara-Jean Anne

DirectorXeris Biopharma Holdings, Inc. (XERS) · full profile →Form 4 · filed Jun 5, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$98K
Net Open-Market Flow
-$98K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 4, 2026Sell(S)16K$6.09$98K127K
Jun 4, 2026Grant(A)24K—$0151K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 4, 2026Grant(A)33K$6.15$203K33K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001635065-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML